跳至主要内容
临床试验/DRKS00004739
DRKS00004739招募中未知

ProImmun Study- Influence of an endurance exercise program on the immune function and quality of life of prostate cancer patients undergoing Antiandrogen- or Chemotherapy - ProImmun Study

Stiftung Leben mit Krebs0 个研究点目标入组 80 人开始时间: 2013年3月5日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
Male

入选标准

  • •Patients with advanced prostate cancer receiving Antiandrogen therapy for at least 4 weeks or
  • •Patients with advanced prostate cancer receiving Antiandrogen therapy in combination with chemotherapy (baseline test before chemotherapy)
  • •Hemoglobin > 9g/dl
  • •Ejection fraction > 60%
  • •forced expiratory volume in one second > 50%
  • •Age > 18 years
  • •Expectation of life > 6 month
  • •Written consent
  • •Inconspicuous ultrasound of the patients heart
  • •Inconspicuous ECG (rest and stress)

排除标准

  • •Anemia < 8g/dl
  • •Platelet count < 10000/µl
  • •CNS Metastasis
  • •Planned Surgery
  • •Heart failure (NYHA III-IV)
  • •Coronary disease
  • •Therapy refractory Hypertension
  • •Other internistic diseases that unable patients to exercise
  • •Orthopedic handicaps that unable patients to exercise
  • •Psychological problems which are critical in view of the responsible medical doctor

研究者

发起方
Stiftung Leben mit Krebs

相似试验

进行中(未招募)
不适用
An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-023444-32-DKGlaxoSmithKline341
进行中(未招募)
不适用
A study to evaluate lung treatment and exercise tolerance of COPD patients with a new bronchodilator: GSK573719/GW642444Moderate/severe chronic obstructive pulmonary disease (COPD).MedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-023442-75-EEGlaxoSmithKline341
进行中(未招募)
不适用
An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444 - N/AModerate/severe chronic obstructive pulmonary disease (COPD).MedDRA version: 14.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-023442-75-DEGlaxoSmithKline341
进行中(未招募)
不适用
An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444. - n/aChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-023444-32-GBGlaxoSmithKline341
进行中(未招募)
不适用
An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPD
EUCTR2010-023444-32-CZGlaxoSmithKline341